Loading
AZD3470 is an experimental small-molecule drug from AstraZeneca in phase 2 trials for hodgkin lymphoma and peripheral T-cell lymphomas, aimed at PRMT5 (MTAP-deleted cancers).
AZD3470 is a small-molecule drug developed by AstraZeneca. Its target is PRMT5 (MTAP-deleted cancers) (the sponsor names PRMT5). The sponsor states: AZD3470 is a second-generation, MTAP-selective, MTA-cooperative inhibitor of PRMT5, designed for tumours with MTAP deletion/deficiency. ClinicalTrials.gov describes the intervention as: AZD3470 is a novel, potent and selective, second-generation, MTAP-selective, inhibitor of PRMT5. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in hodgkin lymphoma and peripheral T-cell lymphomas. The largest, NCT06130553, plans to enrol 334 participants with primary completion expected 2028-12-04. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
AZD3470 is a second-generation, MTAP-selective, MTA-cooperative inhibitor of PRMT5, designed for tumours with MTAP deletion/deficiency. Connects to PRMT5 (MTAP-deleted cancers).
1.AZD3470 slips into a pocket on PRMT5 (MTAP-deleted cancers).
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"AZD3470" OR ABSTRACT:"AZD3470") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AZD3470, not a curated reading list.
Shares Hodgkin lymphoma, AstraZeneca and the tag pipeline.
Shares PRMT5 (MTAP-deleted cancers) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares PRMT5 (MTAP-deleted cancers) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.